tiprankstipranks
Advertisement
Advertisement

ITRM Stock Latest News

ITRM Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Pre-EarningsITRM Earnings Report this Week: Is It a Buy, Ahead of Earnings?
14d ago
ITRM
Iterum Therapeutics cut to Hold at Maxim after delisting notice
PremiumThe Fly
Iterum Therapeutics cut to Hold at Maxim after delisting notice
20d ago
ITRM
Iterum Therapeutics downgraded to Hold from Buy at Maxim
PremiumThe Fly
Iterum Therapeutics downgraded to Hold from Buy at Maxim
20d ago
ITRM
Iterum Therapeutics Appeals Nasdaq Delisting, Explores Strategic Alternatives
PremiumCompany Announcements
Iterum Therapeutics Appeals Nasdaq Delisting, Explores Strategic Alternatives
20d ago
8K
ITRM
Morning News Wrap-Up 3/3/26: Tuesday’s Biggest Stock Market Stories!
PremiumMarket News
Morning News Wrap-Up 3/3/26: Tuesday’s Biggest Stock Market Stories!
21d ago
BX
AMD
Why Is Iterum Therapeutics Stock (ITRM) Down Today?
PremiumMarket NewsWhy Is Iterum Therapeutics Stock (ITRM) Down Today?
21d ago
ITRM
NDAQ
Iterum Therapeutics Faces Nasdaq Delisting, Weighs Strategic Options
Premium
Company Announcements
Iterum Therapeutics Faces Nasdaq Delisting, Weighs Strategic Options
22d ago
8K
ITRM
Iterum Therapeutics Shareholders Reject Key Capital Proposals
Premium
Company Announcements
Iterum Therapeutics Shareholders Reject Key Capital Proposals
1M ago
8K
ITRM
Iterum provides business update, expanded market access for Orlynvah
PremiumThe Fly
Iterum provides business update, expanded market access for Orlynvah
1M ago
ITRM
Iterum Therapeutics provides market access update
PremiumThe Fly
Iterum Therapeutics provides market access update
3M ago
ITRM
Iterum Therapeutics provides business update
PremiumThe Fly
Iterum Therapeutics provides business update
3M ago
ITRM
Iterum Therapeutics Faces Nasdaq Listing Compliance Challenge
PremiumCompany Announcements
Iterum Therapeutics Faces Nasdaq Listing Compliance Challenge
3M ago
8K
ITRM
Buy Rating Affirmed for Iterum Therapeutics Amid Strategic Launch of ORLYNVAH and Strong Market Positioning
PremiumRatingsBuy Rating Affirmed for Iterum Therapeutics Amid Strategic Launch of ORLYNVAH and Strong Market Positioning
4M ago
ITRM
Iterum Therapeutics says ORLYNVAH access ‘continues to grow’
Premium
The Fly
Iterum Therapeutics says ORLYNVAH access ‘continues to grow’
4M ago
ITRM
Iterum Therapeutics receives 510(k) clearance for Susceptibility Test Disc
Premium
The Fly
Iterum Therapeutics receives 510(k) clearance for Susceptibility Test Disc
4M ago
ITRM
Buy Rating Maintained for Iterum Therapeutics Despite Initial Challenges, Driven by Unique Market Position of ORLYNVAH
PremiumRatings
Buy Rating Maintained for Iterum Therapeutics Despite Initial Challenges, Driven by Unique Market Position of ORLYNVAH
4M ago
ITRM
Iterum Therapeutics Reports Q3 2025 Financial Results
PremiumCompany Announcements
Iterum Therapeutics Reports Q3 2025 Financial Results
4M ago
ITRM
Iterum Therapeutics’ Earnings Call: Optimism Amid Challenges
PremiumCompany Announcements
Iterum Therapeutics’ Earnings Call: Optimism Amid Challenges
4M ago
ITRM
Iterum Therapeutics sees cash runway into 2Q26
PremiumThe Fly
Iterum Therapeutics sees cash runway into 2Q26
4M ago
ITRM
Iterum Therapeutics sees FY26 ORLYNVAH net product sales $5M-$15M
PremiumThe FlyIterum Therapeutics sees FY26 ORLYNVAH net product sales $5M-$15M
4M ago
ITRM
Iterum Therapeutics reports Q3 non-GAAP EPS (16c) vs. (24c) last year
Premium
The Fly
Iterum Therapeutics reports Q3 non-GAAP EPS (16c) vs. (24c) last year
4M ago
ITRM
Is ITRM a Buy, Before Earnings?
Premium
Pre-Earnings
Is ITRM a Buy, Before Earnings?
5M ago
ITRM

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >